A Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Completed · Phase 3 · Has a placebo group

Conditions studied: Plaque Psoriasis

In brief

The purpose of this study is to determine the safety and efficacy of 2 doses of ABT-874 versus placebo in the treatment of subjects with moderate to severe plaque psoriasis.

Key facts

Study ID

NCT00570986

Run by

AbbVie (prior sponsor, Abbott)

People needed

1465

Starts

2007-11-01

Expected to finish

2009-06-01

Last updated by the study team

2013-02-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject is >= 18 years of age
• Subject had a clinical diagnosis of psoriasis for at least 6 months, and had moderate to severe plaque psoriasis
• Subject is judged to be in generally good health as determined by the principal investigator

You may not qualify if…

• Subject has previous exposure to systemic anti-IL 12 therapy
• Subject cannot discontinue systemic therapies and/or topical therapies for the treatment of psoriasis and cannot avoid UVB or PUVA phototherapy
• Subject is taking or requires oral or injectible corticosteroids
• Subject diagnosed with erythrodermic psoriasis, pustular psoriasis, medication-induced or medication-exacerbated psoriasis or new onset guttate psoriasis
• Subject considered by the investigator, for any reason, to be an unsuitable candidate
• Female subject who is pregnant or breast-feeding or considering becoming pregnant

Where it is running

• Site Reference ID/Investigator# 6697 — Birmingham, Alabama, United States
• Site Reference ID/Investigator# 7015 — Huntsville, Alabama, United States
• Site Reference ID/Investigator# 6728 — Scottsdale, Arizona, United States
• Site Reference ID/Investigator# 6584 — Tucson, Arizona, United States
• Site Reference ID/Investigator# 6696 — Little Rock, Arkansas, United States
• Site Reference ID/Investigator# 6591 — Bakersfield, California, United States
• Site Reference ID/Investigator# 6710 — Fresno, California, United States
• Site Reference ID/Investigator# 7885 — Irvine, California, United States
• Site Reference ID/Investigator# 6872 — Los Angeles, California, United States
• Site Reference ID/Investigator# 7669 — Oceanside, California, United States
• Site Reference ID/Investigator# 6821 — San Diego, California, United States
• Site Reference ID/Investigator# 6832 — San Diego, California, United States
• Site Reference ID/Investigator# 7305 — San Diego, California, United States
• Site Reference ID/Investigator# 7990 — San Francisco, California, United States
• Site Reference ID/Investigator# 6711 — Santa Monica, California, United States
• Site Reference ID/Investigator# 8139 — Torrance, California, United States
• Site Reference ID/Investigator# 7167 — Vallejo, California, United States
• Site Reference ID/Investigator# 7302 — Denver, Colorado, United States
• Site Reference ID/Investigator# 6921 — Longmont, Colorado, United States
• Site Reference ID/Investigator# 6917 — New Haven, Connecticut, United States
• Site Reference ID/Investigator# 6707 — Jacksonville, Florida, United States
• Site Reference ID/Investigator# 7301 — Miami, Florida, United States
• Site Reference ID/Investigator# 7012 — Miami, Florida, United States
• Site Reference ID/Investigator# 6831 — Miami, Florida, United States
• Site Reference ID/Investigator# 6579 — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.